Drugs / trifluridine/tipiracil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07270991 | Dec 2025 → Nov 2030 expected | gastroesophageal adenocarcinoma | Federation Francophone de Cancerologie Digestive | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07270991 ↗ |
| Route | Oral | “35 mg/m2 by mouth twice daily” NCT07270991 ↗ |